All authors contributed to the concept of this article. SS drafted
the manuscript, and YM revised the manuscript. KF collected sam
ples. SS, KF, YK, MIM, GBE, NH, and HI performed experiments. SS,
KF, HI, MN, JA, and YM analyzed the data. YM supervised experi
ments. YM oversaw the project. All authors approved the final ver
sion of the manuscript.
[1] WHO. 2021. Listings of WHO’s response to COVID-19. Retrieved November 17,
2022, from 〈https://www.who.int/news/item/29–06-2020-covidtimeline〉.
[2] Cui Z, Liu P, Wang N, et al. Structural and functional characterizations of in
fectivity and immune evasion of SARS-CoV-2 Omicron. e813 Cell
2022;185:860–71. https://doi.org/10.1016/j.cell.2022.01.019
[3] NIID. 2022. Current Situation of Infection, November 30, 2022. Retrieved
December 19, 2022, from 〈https://www.niid.go.jp/niid/en/2019-ncov-e/〉.
[4] Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron
subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022;608:603–8. https://doi.org/10.
1038/s41586-022-05053-w
[5] Sheward DJ, Kim C, Fischbach J, et al. Evasion of neutralising antibodies by
omicron sublineage BA.2.75. Lancet Infect Dis 2022;22:1421–2. https://doi.org/
10.1016/S1473-3099(22)00524-2
[6] Gruell H, Vanshylla K, Tober-Lau P, et al. Neutralisation sensitivity of the SARSCoV-2 omicron BA.2.75 sublineage. Lancet Infect Dis 2022;22:1422–3. https://
doi.org/10.1016/S1473-3099(22)00580-1
[7] Uraki R, Ito M, Furusawa Y, et al. Humoral immune evasion of the omicron
subvariants BQ.1.1 and XBB. Lancet Infect Dis 2022;23:30–2. https://doi.org/10.
1016/S1473-3099(22)00816-7
[8] japantimes. 2022. Japan to start fourth vaccine shots for elderly and at-risk
groups Wednesday. Retrieved December 2, 2022, from 〈https://www.
japantimes.co.jp/news/2022/05/20/national/fourth-covid-shots-rollout/〉.
[9] Cohen K, Ren S, Heath K, et al. Risk of persistent and new clinical sequelae
among adults aged 65 years and older during the post-acute phase of SARS-CoV2 infection: retrospective cohort study. BMJ 2022;376:e068414. https://doi.org/
10.1136/bmj-2021-068414
[10] Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, co
morbidities, and outcomes among 5700 patients hospitalized with COVID-19 in
the New York City area. JAMA 2020;323:2052–9. https://doi.org/10.1001/jama.
2020.6775
[11] Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of
1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy re
gion, Italy. JAMA 2020;323:1574–81. https://doi.org/10.1001/jama.2020.5394
[12] Auvigne V, Vaux S, Strat YL, et al. Severe hospital events following symptomatic
infection with Sars-CoV-2 Omicron and Delta variants in France, December
2021-January 2022: a retrospective, population-based, matched cohort study.
EClinicalMedicine
2022;48:101455.
https://doi.org/10.1016/j.eclinm.2022.
101455
[13] Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of
BNT162b2 against omicron in Israel. New Engl J Med 2022;386:1712–20. https://
doi.org/10.1056/NEJMoa2201570
[14] Muhsen K, Maimon N, Mizrahi AY, et al. Association of receipt of the fourth
BNT162b2 dose with omicron infection and COVID-19 hospitalizations among
residents of long-term care facilities. JAMA Intern Med 2022;182:859–67.
https://doi.org/10.1001/jamainternmed.2022.2658
[15] Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a fourth dose of covid-19
mRNA vaccine against the omicron variant among long term care residents in
Funding
This work was supported by the Hyogo Prefectural Government
for YM, and JSPS KAKENHI Grant-in-Aid for Research Activity Startup (Grant Number 22K21115) for HI. The funders had no role in this
study.
Declaration of Competing Interest
This statement is to certify that all Authors have seen and ap
proved the manuscript being submitted. We warrant that the article
is the Authors’ original work. We warrant that the article has not
received prior publication and is not under consideration for pub
lication elsewhere. On behalf of all Co-Authors, the corresponding
Author shall bear full responsibility for the submission.
This research has not been submitted for publication nor has it
been published in whole or in part elsewhere. We attest to the fact
that all Authors listed on the title page have contributed significantly
to the work, have read the manuscript, attest to the validity and
legitimacy of the data and its interpretation, and agree to its sub
mission to the Journal of Infection and Public Health.
All authors agree that author list is correct in its content and
order and that no modification to the author list can be made
without the formal approval of the Editor-in-Chief, and all authors
accept that the Editor-in-Chiefs decisions over acceptance or rejec
tion or in the event of any breach of the Principles of Ethical
Publishing in the Journal of lnfection and Public Health being dis
covered of retraction are final.
1071
S. Sutandhio, K. Furukawa, Y. Kurahashi et al.
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
Journal of Infection and Public Health 16 (2023) 1064–1072
Ontario, Canada: test negative design study. BMJ 2022;378:e071502. https://doi.
org/10.1136/bmj-2022-071502
Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA
Covid-19 vaccine in a nationwide setting. N Engl J Med 2022;386:1603–14.
https://doi.org/10.1056/NEJMoa2201688
Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster
vaccine against hospitalization and death from COVID-19 in adults aged over
60 years. Nat Med 2022;28:1486–90. https://doi.org/10.1038/s41591-02201832-0
Tan CY, Chiew CJ, Lee VJ, et al. Effectiveness of a fourth dose of COVID-19 mRNA
vaccine against omicron variant among elderly people in Singapore. Ann Intern
Med 2022;175:1622–3. https://doi.org/10.7326/M22-2042
Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron
BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster.
Nat Med 2022. https://doi.org/10.1038/s41591-022-02162-x
MHLW. 2021. COVID-19 Vaccine Booster Shots (3rd Dose). Retrieved April 17,
2023, from 〈https://www.mhlw.go.jp/stf/covid-19/booster.html〉.
MHLW. 2022. COVID-19 Vaccination Information on the booster shot (fourth
dose). Retrieved April 17, 2023, from 〈https://www.mhlw.go.jp/content/
001012760.pdf〉.
Furukawa K, Tjan LH, Sutandhio S, et al. Cross-neutralizing activity against SARSCoV-2 variants in COVID-19 patients: comparison of 4 waves of the pandemic in
Japan. Open Forum Infect Dis 2021;8:ofab430. https://doi.org/10.1093/ofid/
ofab430
Kurahashi Y, Sutandhio S, Furukawa K, et al. Cross-neutralizing breadth and
longevity against SARS-CoV-2 variants after infections. Front Immunol
2022;13:773652. https://doi.org/10.3389/fimmu.2022.773652
Furukawa K, Tjan LH, Kurahashi Y, et al. Assessment of neutralizing antibody
response against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA
COVID-19 Vaccine. JAMA Netw Open 2022;5:e2210780. https://doi.org/10.1001/
jamanetworkopen.2022.10780
Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by
TMPRSS2-expressing cells. Proc Natl Acad Sci USA 2020;117:7001–3. https://doi.
org/10.1073/pnas.2002589117
Ren Z, Nishimura M, Tjan LH, et al. Large-scale serosurveillance of COVID-19 in
Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and
requirement of booster vaccination to overcome the Omicron’s outbreak. PLoS
One 2022;17:e0266270. https://doi.org/10.1371/journal.pone.0266270
Hsieh CL, Goldsmith JA, Schaub JM, et al. Structure-based design of prefusionstabilized SARS-CoV-2 spikes. Science 2020;369:1501–5. https://doi.org/10.1126/
science.abd0826
[28] Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression trans
fectants with a novel eukaryotic vector. Gene 1991;108:193–9. https://doi.org/
10.1016/0378-1119(91)90434-d
[29] Riggs P. Expression and purification of recombinant proteins by fusion to mal
tose-binding protein. Mol Biotechnol 2000;15:51–63. https://doi.org/10.1385/
MB:15:1:51
[30] Alexandrov A, Dutta K, Pascal SM. MBP fusion protein with a viral protease
cleavage site: one-step cleavage/purification of insoluble proteins. Biotechniques
2001;30:1194–8. https://doi.org/10.2144/01306bm01
[31] Qian W, Sho I, Zhiteng L, et al. Alarming antibody evasion properties of rising
SARS-CoV-2 BQ and XBB subvariants. Cell 2023. https://doi.org/10.1016/j.cell.
2022.12.018
[32] Gangavarapu, K., A.A. Latif, J. Mullen, et al. 2022. Lineage Comparison S.
Retrieved December 20, 2022, from 〈https://outbreak.info/compare-lineages?
pango=Delta&pango=BA.2&pango=BA.2.75&pango=BA.5&pango=BQ.1.1&pango=
XBB&gene=S〉.
[33] Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA.2.75.2, BQ.1.1,
and XBB from mRNA Bivalent Booster. N Engl J Med 2022. https://doi.org/10.
1056/NEJMc2214293
[34] Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines protect rhesus macaques
from SARS-CoV-2. Nature 2021;592:283–9. https://doi.org/10.1038/s41586-02103275-y
[35] Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design en
abled by prototype pathogen preparedness. Nature 2020;586:567–71. https://
doi.org/10.1038/s41586-020-2622-0
[36] Mourier T, Shuaib M, Hala S, et al. SARS-CoV-2 genomes from Saudi Arabia
implicate nucleocapsid mutations in host response and increased viral load. Nat
Commun 2022;13:601. https://doi.org/10.1038/s41467-022-28287-8
[37] Mohammad T, Choudhury A, Habib I, et al. Genomic variations in the structural
proteins of SARS-CoV-2 and their deleterious impact on pathogenesis: a com
parative genomics approach. Front Cell Infect Microbiol 2021;11:765039. https://
doi.org/10.3389/fcimb.2021.765039
[38] Syed AM, Taha TY, Tabata T, et al. Rapid assessment of SARS-CoV-2-evolved
variants using virus-like particles. Science 2021;374:1626–32. https://doi.org/10.
1126/science.abl6184
[39] Gangavarapu, K., A.A. Latif, J. Mullen, et al. 2022. Lineage Comparison N.
Retrieved December 20, 2022, from 〈https://outbreak.info/compare-lineages?
pango=Delta&pango=BA.2&pango=BA.2.75&pango=BA.5&pango=BQ.1.1&pango=
XBB&gene=N〉.
1072
...
論文の公開元へ
